Individuals who have a pathogenic gene variant that causes an autosomal recessive or X-linked disorder (but who often have no clinical findings or symptoms of the disorder) are known as carriers. Carrier screening refers to testing that is performed to determine if an individual is a carrier, assess the risk for the particular disorder in the individual’s offspring, and enable informed reproductive choices. There are many acceptable strategies for carrier screening, including targeted screening for specific conditions (based on ethnicity and family history) and expanded screening to detect multiple conditions simultaneously. Professional organizations, including the American College of Obstetricians and Gynecologists (ACOG) and the American College of Medical Genetics and Genomics (ACMG), provide varying carrier screening recommendations for commonly screened disorders, including cystic fibrosis (CF), fragile X syndrome (FXS), and spinal muscular atrophy (SMA). Carrier screening for these and other disorders may entail single-gene analysis, targeted variant panels, or expanded panels.
This topic discusses carrier screening for genetic disorders; for more information on the use of laboratory tests in screening for fetal aneuploidy and neural tube defects, see the ARUP Consult Prenatal Screening and Diagnosis for Chromosomal Abnormalities and Neural Tube Defects topic.
Quick Answers for Clinicians
The American College of Obstetricians and Gynecologists (ACOG) recommends that information about carrier screening be provided to every woman who is pregnant or planning to become pregnant. The specific tests that should be offered depend on the patient’s family history and ethnic background. Testing is also appropriate in reproductive partners and family members of known carriers, and in gamete (ie, egg or sperm) donors. Ideally, carrier screening should be performed before pregnancy to enable individuals to make informed reproductive decisions ; however, carrier screening can be performed during pregnancy. Regardless of the timing of carrier screening, testing for a specific disorder is typically recommended only once in an individual’s lifetime. For more information, see Indications for Testing.
The American College of Obstetricians and Gynecologists (ACOG) recommends including disorders in carrier screening panels if they (1) have a carrier frequency of 1:100 or greater; (2) exhibit a well-defined phenotype; (3) have a detrimental effect on quality of life; (4) result in cognitive or physical impairment; (5) require surgical or medical intervention; and (6) have an onset early in life. The American College of Medical Genetics and Genomics (ACMG) recommends including disorders on screening panels if at-risk individuals would consider a prenatal diagnosis of those disorders to be beneficial for decision-making purposes. The carrier risks and detection rates should be known so that residual risk can be calculated, and the clinical associations between pathogenic variants and disease severity should be well defined. Disorders with variable expressivity, incomplete penetrance, or a mild phenotype should be considered optional for inclusion in panels.
Although molecular genetic techniques are used to screen for most disorders, biochemical or hematologic testing is appropriate in some cases (eg, hemoglobin electrophoresis for hemoglobinopathies or biochemical [enzyme] testing for Tay-Sachs disease). See Carrier Screening Tests for more information.
No. Carrier screening is not a substitute for newborn screening, and vice versa. Newborn screening tests are state mandated and are intended to detect, at an early age, disorders for which a treatment or intervention is available. Given that carriers may never develop any signs or symptoms of disease, newborn screening tests are not suitable for identifying carriers. Carrier screening is intended to determine if an individual has a variant associated with a genetic disease, and therefore has the potential to pass that disease to offspring. Furthermore, newborn screening and carrier screening panels may test for different conditions. For more information on newborn screening, see the CDC Newborn Screening Portal.
Indications for Testing
Carrier testing may be offered or recommended based on a variety of factors such as ethnicity, family history, or abnormal ultrasound findings. If an individual is identified as a carrier of an autosomal recessive disorder, that person’s reproductive partner should be offered carrier screening for that disorder, or simultaneous testing can be offered to both partners. Testing for a particular disorder is usually recommended only once in a person’s lifetime, unless a genetics professional determines that advances in testing (eg, new methodologies or the discovery of additional variants associated with a specific disease) warrant rescreening.
Professional organizations offer the following recommendations for commonly screened conditions.
Offer screening to all women who are pregnant or considering pregnancy
A panel of the most common CFTR variants (present in at least 0.1% of the population) associated with classic CF is recommended
Complete sequencing of the CFTR gene is not appropriate for carrier screening
|FXS||Offer screening to women with a family history of FXS or intellectual disability suggestive of FXS, ovarian insufficiency, ovarian failure, or elevated follicle-stimulating hormone before age 40 yrs|
|SMA||Offer screening to all women who are pregnant or considering pregnancy, regardless of ancestry or family history|
Perform a CBC in all women who are pregnant or, ideally, considering pregnancy
Perform hemoglobin electrophoresis for individuals of African, Mediterranean, Middle Eastern, Southeast Asian, or West Indian descent or if a hemoglobinopathy is suspected based on CBC results
|Ashkenazi Jewish genetic diseases||
Offer screening to individuals of Ashkenazi Jewish descent who are pregnant or planning to become pregnant
Tay-Sachs screening should be offered to all individuals of Ashkenazi Jewish, French-Canadian, or Cajun descent
Carrier Screening Tests
Screening tests may take the form of biochemical tests for a single disorder (eg, hexosaminidase A testing for Tay-Sachs disease), single-gene sequencing or deletion/duplication tests (eg, copy number analysis for the SMN1 gene in SMA), targeted panels (eg, panel tests for common CFTR variants in CF), or expanded carrier screening panels. Regardless of the strategy used, genetic counseling is recommended.
Individual conditions commonly screened for include CF, FXS, and SMA. For more information on CF tests, see the ARUP Consult Cystic Fibrosis topic and the Cystic Fibrosis (CFTR) 165 Pathogenic Variants Test Fact Sheet. For information on FXS, see the Fragile X Syndrome Test Fact Sheet. For more information on SMA, see the Spinal Muscular Atrophy Test Fact Sheet. Ethnicity-based carrier screening for hemoglobinopathies using biochemical tests is also recommended; see the ARUP Consult Hemoglobinopathies topic for more information.
Expanded Carrier Screening Panels
Expanded carrier screening for multiple disorders using a panel of genetic and/or biochemical tests can be considered for individuals from specific ethnic backgrounds (eg, multigene panels for individuals of Ashkenazi Jewish descent) or for couples with consanguinity, or can be considered for all individuals regardless of ethnicity (panethnic screening), given the difficulty of precisely determining an individual’s ethnic background and the associated difficulty of estimating carrier risk. Decisions about which disorders to include on a screening panel should be based on the background, family history, and needs of the patient. Consultation with a genetic counselor is recommended to assist in selecting the right tests.
For more information on expanded screening for individuals of Ashkenazi Jewish descent, see the ARUP Consult Ashkenazi Jewish Genetic Diseases topic, Ashkenazi Jewish Genetic Diseases Carrier Screening Algorithm, and Ashkenazi Jewish Genetic Diseases Panel Test Fact Sheet.
Interpretation of Results
A negative result on a carrier screening test indicates that no pathogenic variant has been detected; therefore, the carrier risk is reduced, but not eliminated. A positive result on a carrier screening test indicates that one or more pathogenic variants were detected, and that the individual is predicted to be a carrier of specific disorders.
If an individual is identified as a carrier of one or more autosomal recessive disorders, that person’s reproductive partner or gamete donor should be offered carrier screening for the disorder(s). Genetic consultation is also recommended. If a female is identified as a carrier of an X-linked recessive disorder, carrier screening is typically not indicated for the male reproductive partner. Couples identified as carriers of the same disorder may elect to pursue reproductive options such as prenatal diagnosis, gamete donation with in vitro fertilization, or preimplantation genetic diagnosis.
Relatives of individuals with an identified pathogenic variant are also at risk of being carriers of the variant(s) and should be offered screening. ACOG recommends that patients identified as carriers be encouraged to inform relatives of the risk.
ARUP Laboratory Tests
Screening for genetic variants that indicate carrier status for CF, FXS, and SMA in pregnant couples or those planning a pregnancy
Do not use for diagnostic testing in patients with symptoms of CF, FXS, or SMA
Polymerase Chain Reaction/Fluorescence Monitoring, Polymerase Chain Reaction/Capillary Electrophoresis, Multiplex Ligation-dependent Probe Amplification
Carrier screening for expectant individuals and those planning a pregnancy AND diagnostic testing for individuals with symptoms of classic CF
Polymerase Chain Reaction/Fluorescence Monitoring
Preferred test to diagnose FXS, for carrier screening in individuals with a positive family history, or for routine carrier screening
Polymerase Chain Reaction/Capillary Electrophoresis
Diagnostic or carrier testing for SMA
Test also includes 2 SMN1 variants that are part of a haplotype associated with SMN1 duplication in silent carriers, especially in Ashkenazi Jewish and Asian populations
Multiplex Ligation-dependent Probe Amplification
Prenatal or preconception carrier screening for over 100 disorders using next generation sequencing (NGS); intended for individuals or couples in the general population
Refer to Myriad Women's Health for more test information
Massively Parallel Sequencing/Polymerase Chain Reaction
Prenatal or preconception carrier screening for over 100 disorders, including FXS, using NGS; intended for individuals or couples in the general population
Refer to Myriad Women's Health for more test information
ACOG Committee on Genetics. ACOG Committee Opinion No. 691: carrier screening for genetic conditions. Obstet Gynecol. 2017;129(3):e41-e55.
Edwards JG, Feldman G, Goldberg J, et al. Expanded carrier screening in reproductive medicine—points to consider: a joint statement of the American College of Medical Genetics and Genomics, American College of Obstetricians and Gynecologists, National Society of Genetic Counselors, Perinatal Quality Foundation, and Society for Maternal-Fetal Medicine. Obstet Gynecol. 2015;125(3):653-662.
ACOG Committee on Genetics. ACOG Committee Opinion No. 690: carrier screening in the age of genomic medicine. Obstet Gynecol. 2017;129(3):e35-e40.
Grody WW, Thompson BH, Gregg AR, et al. ACMG position statement on prenatal/preconception expanded carrier screening. Genet Med. 2013;15(6):482-483.
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Newborn screening portal. [Last reviewed: Feb 2019; Accessed: Jul 2020]
Westemeyer M, Saucier J, Wallace J, et al. Clinical experience with carrier screening in a general population: support for a comprehensive pan-ethnic approach [published correction appears in Genet Med. 2020;22(7):1282]. Genet Med. 2020;22(8):1320-1328.